Venous Thromboembolism Prophylaxis in Intensive Care Units (Review)

Venous thromboembolism (VTE) is the third most frequent cause of death from cardiovascular diseases after myocardial infarction and stroke and the most preventable cause of mortality. VTE is common and potentially life-threatening in patients admitted to ICU, even in spite of preventive care.

The purpose of the review is to justify the necessity of preventive care for venous thromboembolism in ICU patients.

From over 300 initially selected sources of literature databases (Scopus, Web of science, RSCI, etc.), 99 sources were chosen including 69 that were published during the last five years (2015-2020). The exclusion criteria included data of low informative value or disproven data.

The review discusses VTE relevance, risk factors for its development, selection and scope of preventive care depending on the risk of thrombosis and hemorrhage, patient management in different clinical settings (impaired renal function, thrombocytopenia, heparin-induced thrombocytopenia, liver dysfunction, indications for installation of vena cava filter).

In the world literature, however, there is yet no consensus on the matter under discussion that would have been based on meta-analyses or large randomized studies. No agreement has been reached either in respect of use of mechanical and combined prophylaxis of venous thromboses/PATE, application of ultrasound to detect asymptomatic thromboses. There are no studies on efficacy and safety of pharmacological prophylaxis of VTE in patients with significant hepatic impairment.

The review describes that all patients admitted in ICU feature a high risk of VTE development. The scope of preventive care depends not only on VTE risk but also on the risk of a hemorrhage. To prevent the latter, low-molecular weight heparins should be used. For most cases, the choice of heparine dose depends on renal function. When there is a high risk of hemorrhage, mechanical preventive aids are applied.

1. Benjamin E.J., Virani S.S., Callaway C.W., Chamberlain A.M., Chang A.R., Cheng S., Chiuve S.E., Cushman M., Delling F.N., Deo R., de Ferranti S.D., Ferguson J.F., Fornage M., Gillespie C., Isasi C.R., Jimenez M. C., Jordan L.C., Judd S.E., Lackland D., Lichtman J.H., Lisabeth L., Liu S., Longenecker C.T., Lutsey P.L., Mackey J.S., Matchar D.B., Matsushita K., Mussolino M.E., Nasir K., O’Flaherty M., Palaniappan L.P., Pandey A., Pandey D.K., Reeves M.J., Ritchey M.D., Rodriguez C.J., Roth GA., Rosamond W.D., Sampson U.K.A, Satou G.M., Shah S.H., Spartano N. L., TirschwellD.L., Tsao C.W., VoeksJ.H., WilleyJ.Z., WilkinsJ.T., Wu J.H., Alger H.M., Wong S.S., Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018; 137 (12): 67-492. DOI: 10.1161/CIR.0000000000000558. PMID: 29386200

2. Wendelboe A.M., Raskob G.E. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 2016; 118 (9): 1340-1347. DOI: 10.1161/CIRCRESAHA.115.306841. PMID: 27126645

3. Keller K., Hobohm L., Ebner M., Kresoja K.P., Munzel T., Konstantinides S.V, LankeitM. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. Eur Heart J. 2020; 41, 522-529. DOI: 10.1093/eurheartj/ehz236. PMID: 31102407

4. Lehnert P, Lange T., Moller C.H., Olsen P.S., Carlsen J. Acute Pulmonary Embolism in a National Danish Cohort: Increasing Incidence and Decreasing Mortality. Thromb Haemost. 2018; 118 (3): 539-546. DOI: 10.1160/TH17-08-0531. PMID: 29536465

5. Cohen A.T., Agnelli G., Anderson FA., Arcelus J.I., Bergqvist D., Brecht J.G., GreerI.A., Heit J.A., Hutchinson J.L., Kakkar A.K., Mottier D., Oger E. , Samama M.M., Spannagl M.; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE)in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98 (04): 756-764. DOI: 10.1160/th07-03-0212. PMID: 17938798

6. Beckman M.G., Hooper W.C., Critchley S.E., Ortel T.L. Venous thromboembolism: a public health concern. Am J Prev Med. 2010; 38 (4): S495-501. DOI: 10.1016/j.amepre.2009.12.017. PMID: 20331949

7. Fernandez M.M., Hogue S., Preblick R., Kwong W.J. Review of the cost of venous thromboembolism. Clinicoecon Outcomes Res. 2015; 7: 451-462. DOI: 10.2147/CEOR.S85635. PMID: 26355805

8. Barco S., WoerschingA.L., Spyropoulos A.C., Piovella F., Mahan C.E. European Union-28: an annualised cost-of-illness model for venous thromboembolism. Thromb Haemost. 2016; 115 (4): 800-808. DOI: 10.1160/TH15-08-0670. PMID: 26607486

9. Schunemann H.J., Cushman M., Burnett A.E., Kahn S.R., Beyer-We-stendorf J., Spencer EA., Rezende S.M., Zakai N.A., Bauer K.A., Dentali F. , Lansing J., Balduzzi S., Darzi A., Morgano G.P., Neumann I., Nieuwlaat R., Yepes-Nunez J.J., Zhang Y., Wiercioch W. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018; 2 (22): 3198-3225. DOI: 10.1182/blo-odadvances.2018022954. PMID: 30482763

10. The Lancet Haematology. Thromboembolism: an under appreciated cause of death. Lancet Haematol. 2015; 2 (10): 393. DOI: 10.1016/ S2352-3026 (15)00202-1. PMID: 26686033

11. Raskob E.G. and ISTH Steering Committee for World Thrombosis Day. Venous thromboembolism: A Call for risk assessment in all hospitalised patients. Thromb Haemost. 2016; 116 (5): 777-779. DOI: 10.1160/TH16-09-0732. PMID: 27734070

12. Stone J., Hangge P., Albadawi H., Wallace A., Shamoun F., Knuttien M. G., Naidu S., Oklu R. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther. 2017; 7 (3): 276-284. DOI: 10.21037/cdt.2017.09.01. PMID: 29399531

13. Achaibar K., Waldmann C. Prevention of venous thromboembolism in the critically ill patient. J Intensive Care Soc. 2015; 16 (3): 199-201. DOI: 10.1177/1751143715569404. PMID: 28979410

14. Alikhan R., Peters F., WilmottR., Cohen A.T. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol. 2004; 57 (12): 1254-1257. DOI: 10.1136/jcp.2003.013581. PMID: 15563663

15. Castellucci L.A., WellsP.S., DuffetL. Nonleg venous thrombosis in critically ill adults. JAMA. 2015; 313 (4): 411-412. DOI: 10.1001/jama. 2014.12496. PMID: 25626038

16. Lim W., Meade M., Lauzier F., Zarychanski R., Mehta S., Lamontagne F., Dodek P., McIntyre L., Hall R., Heels-Ansdell D., Fowler R., Pai M., Guyatt G., Crowther M.A., Warkentin T.E., Devereaux P.J., Walter S.D., Muscedere J., Herridge M., Turgeon A.F., Geerts W., Finfer S., Jacka M., Berwanger O., Ostermann M., Qushmaq I., Friedrich J.O., Cook D.J.; PROphylaxis for ThromboEmbolism in Critical Care Trial Investigators. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients. Crit Care Med. 2015; 43 (2): 401410. DOI: 10.1097/CCM.0000000000000713. PMID: 25474533

17. Minet C., Potton L., Bonadona A., Hamidfar-Roy R., Somohano C.A., Lugosi M., Cartier J.C., Ferretti G., Schwebel C., Timsit J.F. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Crit Care. 2015; 19: 287. DOI: 10.1186/s13054-015-1003-9. PMID: 26283414

18. Miri M., Goharani R., SistanizadМ. Deep Vein Thrombosis among Intensive Care Unit Patients; an Epidemiologic Study. Emerg (Tehran). 2017; 5 (1): 13. DOI: 10.22037/emergency.v5i1.11622. PMID: 28286820

19. Prichayudh S., Tumkosit M., Sriussadaporn S., Samorn P., Pak-artR., Sriussadaporn S., Kritayakirana K. Incidence and associated factors of deep venous thrombosis in Thai surgical ICU patients without chemoprophylaxis: one year study. J Med Assoc Thai. 2015; 98 (5): 472-478. PMID: 26058275

20. KaplanD., CasperT.C.,ElliottC.G.,MenS.,PendletonR.C.,KraissL.W., Weyrich A.S., Grissom C.K., Zimmerman G.A., Rondina M.T. VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. Chest. 2015; 148 (5): 1224-1230. DOI: 10.1378/chest.15-0287. PMID: 26111103

21. Dimopoulos G., Paignerelli M., Berre J., Salmon I., Vincent J.L. Post mortem examination in the intensive care unit: still useful? Intensive Care Med. 2004; 30 (11): 2080-2085. DOI: 10.1007/s00134-004-2448-5. PMID: 15480565

22. Greene R., Zapol W.M., Snider M.T., Reid L., Snow R., O’Connell R.S., Novelline R.A. Early bedside detection of pulmonary vascular occlusion during acute respiratory failure. Am Rev Respire Dis. 1981; 124 (5): 593-601. DOI: 10.1164/arrd.1981.124.5.593. PMID: 7305115

23. Lilly C.M., Liu X., Badawi O., Franey C.S., Zuckerman I.H. Thrombosis prophylaxis and mortality risk among critically ill adults. Chest. 2014; 146 (1): 51-57. DOI: 10.1378/chest.13-2160. PMID: 24722879

24. Malato A, Dentali F., Siragusa S., Fabbiano F., Kagoma Y., Boddi M., Gensini G.F., Peris A., Crowther M., Napolitano M. The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfus. 2015; 13 (4): 559-568. DOI: 10.2450/2015.0277-14. PMID: 26513770

25. Konstantinides S.V, Meyer G., Becattini C., Bueno H., Geersing G.J., Harjola VP, Huisman M.V., Humbert M., Jennings C.S., Jimenez D., Kucher N. , Lang I.M., Lankeit M., Lorusso R., Mazzolai L., Meneveau N., Ni Ainle F., Prandoni P., Pruszczyk P., Righini M., Torbicki A., Van Belle E., Zamorano J.L.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2019; 00: 1-61. DOI: 10.1093/eurheartj/ehz405. PMID: 31504429

26. Barbar S., Prandoni P. Scoring systems for estimating risk of venous thromboembolism in hospitalized medical patients. Semin Thromb Hemost. 2017; 43 (5): 460-468. DOI: 10.1055/s-0036-1597901. PMID: 28166598

27. Bokeriya L.A., Zatevakhin I.I., Kirienko A.I., Andriyashkin A.V, And-riyashkin V.V., Arutyunov G.P., Barinov V.E., Bicadze V.O., Bodyhov M.K., BritovA.N., ButenkoA.V., Vavilova T.V., Voro’evaN.A., Voskanyan Yu.E., Gavrilenko A.V., Galstyan G.M., GelfandB.R., GilyarovM.Yu., Golubev G.Sh., Zamyatin M.N., Zolotuhin IA., Kobalava Zh.D., Katel-nickijI.I., Kopenkin S.S., KuznecovM.R., Leont’evS.G., LobastovK.V., Obastov K.V., Lubnin A.Yu., Makacariya A.D., Moiseev VS., Momot A.P., Ostryakova E. V, Panchenko E.P., Perekhodov S.N., Piradov M.A., Pod-dubnaya I.V., Pokrovskij A.V., Procenko D.N., Prudkov M.I., Pryadko S.I., PyregovA.V., Reshetnyak T.M., RyabinkinaYu.V., Sapelkin S.V, Semenova M.N., Smirnov S.V, Sokolov V.A., Stakhovskaya L.V., Stojko Yu.M., Sulimov V.A., Sukhih G.T., Tereshchenko S.N., Fokin A.A., Hru-slovM.V., ShevelaA.I., Shimanko A.I., Shulutko A.M., YavelovI.S., Ya-hontov D.I. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEC). Flebologiya. 2015; 9 (4-2): 1-52.

28. Rovinski D., Ramos R.B., Fighera T.M., Casanova G.K., Spritzer P.M. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thromb Res. 2018; 168: 83-95. DOI: 10.1016/j.throm-res.2018.06.014. PMID: 29936403

29. Chew H.K., Wun T., Harvey D., Zhou H., White R.H. Incidence of venous hromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166 (4): 458-464. DOI: 10.1001/archinte.166.4.458. PMID: 16505267

30. Timp J.F., Braekkan S.K., VersteegH.H., Cannegieter S.C. Epidemiology of cancerassociated venous thrombosis. Blood. 2013; 122 (10): 17121723. DOI: 10.1182/blood-2013-04-460121. PMID: 23908465

31. van Vlijmen E.F., Wiewel-Verschueren S., Monster T.B., MeijerK. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Hae-most. 2016; 14 (7): 1393-1403. DOI: 10.1111/jth.13349. PMID: 27121914

32. Piazza G., Goldhaber S.Z., LessardD.M., GoldbergR.J., Emery C., Spencer F.A. Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost. 2011; 106 (6): 1095-1102. DOI: 10.1160/TH11-07-0469. PMID: 22012325

33. Fontaine G.V., Vigil E., Wohlt PD., Lloyd J.F., Evans R.S., Collingridge D.S., Stevens S.M., Woller S.C. Venous Thromboembolism in Critically Ill Medical Patients Receiving Chemoprophylaxis: A Focus on Obesity and Other Risk Factors. Clin Appl Thromb Hemost. 2016; 22 (3): 265-273. DOI: 10.1177/1076029615604048. PMID: 26346440

34. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE. 2018. URL: https: //www.nice.org.uk/guidance/ng89 (30 oct 2019).

35. Cook D., Crowther M., Meade M., Rabbat C., Griffith L., Schiff D., Ge-erts W., Guyatt G. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med. 2005, 33 (7): 1565-1571. DOI: 10.1097/01.CCM.0000171207.95319.B2. PMID: 16003063

36. Kumar A., Mehta Y., Ali T., Gupta M.K., George J.V. Deep vein thrombosis in medical and surgical Intensive Care Unit patients in a Tertiary Care Centre in North India: Incidence and risk factors. J Anaesthesiol Clin Pharmacol. 2017; 33 (2): 181-186. DOI: 10.4103/0970-9185.209760. PMID: 28781442

37. Hunt B.J. Preventing Venous Thromboembolism in the Critically Ill — Can We do More? J Intensive Care Soc. 2014; 15 (3): 3-5. DOI: 10.1177/17511437140151S302

38. Zhang Ch., Zhang Z., Mi J., Wang X., Zou Y., Chen X., Nie Z., Luo X., Gan R. The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis. Medicine (Baltimore). 2019; 98 (23): 15833. DOI: 10.1097/MD.0000000000015833. PMID: 31169685

39. Viarasilpa T., Panyavachiraporn N., Marashi S.M., Van Harn M., Kowalski R.G., Mayer S.A. Prediction of Symptomatic Venous Thromboembolism in Critically Ill Patients: The ICU-Venous Thromboembolism Score. Crit Care Med. 2020. DOI: 10.1097/CCM.0000000000004306. PMID: 32187076

40. WhiteD., Woller S.C., Stevens S.M., CollingridgeD.S., Chopra V., Fontaine G.V. Comparative thrombosis risk of vascular access devices among critically ill medical patients. Thromb Res. 2018; 172: 54-60. DOI: 10.1016/j.thromres.2018.10.013. PMID: 30384035

41. KaplanD., CasperT.C.,Elliott C.G.,MenS.,PendletonR.C.,KraissL.W., Weyrich A.S., Grissom C.K., Zimmerman G.A., Rondina M.T. VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. Chest. 2015, 148 (5): 1224-1230. DOI: 10.1378/chest.15-0287. PMID: 26111103

42. Kovacic A.P.M., Caprnda M., Mrhar A., Kubatka P., Locatelli I., Zolakova B., Gaspar L., Prosecky R., Kruzliak P., Staffa R., Rodrigo L., Ra-donak J., Petrovic D. Impact of drugs on venous thromboembolism risk in surgical patients. Eur J Clin Pharmacol. 2019; 75 (6): 751-767. DOI: 10.1007/s00228-019-02636-x. PMID: 30719565

43. Jonsson A.K., Schill J., Olsson H., Spigset O., Hagg S. Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence. CNS Drugs. 2018; 32 (1): 47-64. DOI: 10.1007/s40263-018-0495-7. PMID: 29423659

44. Masopust J., Bazantova V, Kuca K., Klimova B., Valis M.. Venous Thromboembolism as an Adverse Effect During Treatment With Olanzapine: A Case Series. Front Psychiatry. 2019; 10: 330. DOI: 10.3389/fpsyt.2019.00330. PMID: 31156478

45. Duranteau J., Taccone F.S., Verhamme P., Ageno W.; ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: Intensive care. Eur J Anaesthesiol. 2018; 35 (2): 142-146. DOI: 10.1097/EJA.0000000000000707. PMID: 29112545

46. Kahn S.R., Lim W., Dunn A.S., Cushman M., Dentali F., Akl E.A., Cook D.J., Balekian A.A., Klein R.C., Le H., Schulman S., Murad M.H. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (2): e195S-e226S. DOI: 10.1378/chest.11-2296. PMID: 22315261

47. Arabi Y.M., Burns K.E.A., Alsolamy S.J., Alshahrani M.S., Al-Hameed F.M., Arshad Z., Almaani M., Hawa H., Mandourah Y., Almekhlafi GA., Al Aithan A., Khalid I., Rifai J., Rasool G., Abdukahil SA.I., Jose J., Afesh L. Y., Al-Dawood A.; Saudi Critical Care Trials Group. Surveillance or no surveillance ultrasonography for deep vein thrombosis and outcomes of critically ill patients: a pre-planned sub-study of the PREVENT trial. Intensive Care Med. 2020; 46 (4): 737-746. DOI: 10.1007/s00134-019-05899-1. PMID: 32095845

48. Greene M.T., Spyropoulos A.C., Chopra V., Grant PJ., Kaatz S., Bernstein S.J., Flanders S.A. Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients. Am J Med. 2016; 129 (9): 1001.e9-1001.e18. DOI: 10.1016/j.amjmed.2016.03.031. PMID: 27107925

49. Stuck A.K., Spirk D., Schaudt J., Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review. Thromb Haemost. 2017; 117 (4): 801-808. DOI: 10.1160/TH16-08-0631. PMID: 28150851

50. Schunemann H.J., Cushman M., Burnett A.E., Kahn S.R., Beyer-Westendorf J., Spencer FA., Rezende S.M., Zakai N.A., Bauer K.A., Dentali F., Lansing J., Balduzzi S., Darzi A., Morgano G.P., Neumann I., Nie-uwlaat R., Yepes-Nunez J.J., Zhang Y., Wiercioch W. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018; 2 (22): 3198-3225. DOI: 10.1182/blo-odadvances.2018022954. PMID: 30482763

51. Novikova N.A., Shilova A.S. Профилактика венозных тромбоэмболических осложнений в терапевтической практике. Meditsinskij sovet. 2017; 7: 43-47 [In Russ.]. DOI: 10.21518/2079-701X-2017-7-43-47.

52. Barbar S., Noventa F, Rossetto V, Ferrari A., Brandolin B., Perlati M., De Bon E., Tormene D., Pagnan A., Prandoni P. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010; 8 (11): 2450-2457. DOI: 10.1111/j.1538-7836.2010.04044.x. PMID: 20738765

53. Spyropoulos A.C., Anderson F.A. Jr., FitzGerald G., Decousus H., Pini M., Chong B.H., Zotz R.B., Bergmann J.F., Tapson V., Froehlich J.B., MonrealM., Merli G.J., Pavanello R., TurpieA.G.G., NakamuraM., Piovella F, Kakkar A.K., Spencer FA.; IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011; 140 (3): 706-714. DOI: 10.1378/chest.10-1944. PMID: 21436241

54. Caprini J.A. Thrombotic risk assessment: a hybrid approach [Электронный ресурс]. http://www.venousdisease.com / Publications / J.A. Caprini-Hybrid Approach 3-10-05.pdf. Accessed 01.08.17 http://www.venousdisease.com/Publication. DOI: 10.1016/B978-012369515-4/50044-2

55. Pannucci C.J., Swistun L., MacDonald J.K., Henke P.K., Brooke B.S. Individualized Venous Thromboembolism Risk Stratification Using the 2005 Caprini Score to Identify the Benefits and Harms of Chemoprophylaxis in Surgical Patients: A Meta-analysis. Ann Surg. 2017; 265 (6): 1094-1103. DOI: 10.1097/SLA.0000000000002126. PMID: 28106607

56. Fu Y., Liu Y., Chen S., Jin Y., Jiang H. The combination of Caprini risk assessment scale and thrombotic biomarkers to evaluate the risk of venous thromboembolism in critically ill patients. Medicine (Baltimore). 2018; 97 (47): 13232. DOI: 10.1097/MD.0000000000013232. PMID: 30461624

57. Xu J.X., Dong J., Ren H., Chen X.J., Yang Y., Chen R.X., Wang G.D., Wang H.Z. Incidence and risk assessment of venous thromboembolism in cancer patients admitted to intensive care unit for postoperative care. J BUON. 2018; 23: 500-506. PMID: 29745099

58. Bateman D.K., Dow R.W., Brzezinski A., Bar-Eli H.Y., Kayiaros S.T. Response to the Letter to the Editor on «Correlation of the Caprini Score and Venous Thromboembolism Incidence Following Primary Total Joint Arthroplasty-Results of a Single-Institution Protocol». J Arthroplasty. 2018; 33 (8): 2698-2699. DOI: 10.1016/j.arth.2018.03.064. PMID: 29735184

59. Arnold D.M., Donahoe L., Clarke FJ., Tkaczyk A.J., Heels-Ansdell D., Zytaruk N., Cook R., Webert K.E., McDonald E., Cook D.J. Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med. 2007; 30 (2): 93-102. DOI: 10.25011/cim.v30i2.985. PMID: 17716547

60. Krag M., Perner A., Wetterslev J., Wise M.P., Borthwick M., Bendel S., McArthur C., Cook D., Nielsen N., Pelosi P., Keus F, Guttormsen A.B., Moller A.D., Mоller M.H.; SUP-ICU co-authors. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med. 2015; 41 (5): 833-845. DOI: 10.1007/s00134-015-3725-1. PMID: 25860444

61. Marker S., KragM., Moller M.H. What’s new with stress ulcer prophylaxis in the ICU? Intensive Care Med. 2017; 43 (8): 1132-1134. DOI: 10.1007/s00134-017-4733-0. PMID: 28238056

62. MazzefM., Kiefer J., Greenwood J., Tanaka K., Menaker J., Kon Z., Sanchez P., Pham S., Herr D. Epidemiology of gastrointestinal bleeding in adult patients on extracorporeal life support. Intensive Care Med. 2015; 41 (11): 2015. DOI: 10.1007/s00134-015-4006-8. PMID: 26264245

63. Luyt C.E., Brechot N., Demondion P., Jovanovic T., Hekimian G., Leb-reton G., Nieszkowska A., Schmidt M., Trouillet J.L., Leprince P., Chastre J., Combes A. Brain injury during venovenous extracorporeal membrane oxygenation. Intensive Care Med. 2016; 42 (5): 897-907. DOI: 10.1007/s00134-016-4318-3. PMID: 27007107

64. Ejaz A., Ahmed M.M., Tasleem A., Rafay Khan Niazi M., Ahsraf M.F., Ahmad I., Zakir A., Raza A. Thromboprophylaxis in Intensive Care Unit Patients: A Literature Review. Cureus. 2018; 10 (9): e3341. DOI: 10.7759/cureus.3341. PMID: 30473974

65. HostlerD.C., MarxE.S., MooresL.K., Petteys S.K., Hostler J.M., Mitchell J. D., Holley PR., Collen J.F., Foster B.E., Holley A.B. Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score. Chest. 2016; 149 (2): 372-379. DOI: 10.1378/chest.14-2842. PMID: 26867833

66. Rosenberg D.J., Press A., Fishbein J., Lesser M., McCullagh L., McGinn T., SpyropoulosA.C. External validation of the IMPROVE bleeding risk assessment model in medical patients. Thromb Haemost. 2016; 116 (3) : 530-536. DOI: 10.1160/TH16-01-0003. PMID: 27307054

67. Zeidan A.M., Streiff M.B., Lau B.D., Ahmed S.R., Kraus PS., Hobson D.B., Carolan H., Lambrianidi C., Horn P.B., Shermock K.M., Tinoco G., Siddiqui S., Haut E.R. Impact of a venous thromboembolism prophylaxis «smart order set»: Improved compliance, fewer events. Am J Hematol. 2013; 88 (7): 545-549. DOI: 10.1002/ajh.23450. PMID: 23553743

68. Mitchell J.D., Collen J.F., Petteys S., Holley A.B. A simple reminder system improves venous thromboembolism prophylaxis rates and reduces thrombotic events for hospitalized patients. J Thromb Haemost. 2012; 10 (2): 236-243. DOI: 10.1111/j.1538-7836.2011.04599.x. PMID: 22188121

69. Lau B.D., Haut E.R. Practices to prevent venous thromboembolism: a brief review. BMJ Qual Saf. 2014; 23 (3): 187-195. DOI: 10.1136/ bmjqs-2012-001782. PMID: 23708438

70. Cade J.F. High risk of the critically ill for venous thromboembolism. Crit Care Med. 1982; 10 (7): 448-450. DOI: 10.1097/00003246-198207000-00006. PMID: 7044682

71. Welsby I., Ortel T.L. Is the time for individualized thromboprophylaxis regimens in ICU? Crit Care Med. 2015; 43 (2): 500-501. DOI: 10.1097/CCM.0000000000000784. PMID: 25599484

72. BoonyawatK., CrowtherM.A. Venous thromboembolism prophylaxis in critically ill patients. Semin Thromb Hemost. 2015; 41 (1): 68-74. DOI: 10.1055/s-0034-1398386. PMID: 25594495

73. Alhazzani W., Lim W., Jaeschke R.Z., Murad M.H., Cade J., Cook D.J. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2013; 41 (9): 2088-2098. DOI: 10.1097/CCM.0b013e31828cf104. PMID: 23782973

74. Beitland S., Sandven I., Kj^rvik L.K., Sandset PM., Sunde K., Eken T. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2015; 41 (7): 1209-1219. DOI: 10.1007/s00134-015-3840-z. PMID: 25971389

75. Stelfox H.T., Brundin-Mather R., Soo A., Parsons Leigh J., Ni ven D.J., Fiest K. M., DoigC.J.,ZuegeD.J., KushnerB., ClementF., Straus S.E., CookD.J., Bagshaw S.M., Sauro K.M. A multicentre controlled pre-post trial of an implementation science intervention to improve venous thromboembolism prophylaxis in critically ill patients. Intensive Care Med. 2019; 45 (2): 211-222. DOI: 10.1007/s00134-019-05532-1. PMID: 30707246

76. Pai M., Adhikari N.K.J., Ostermann M., Heels-AnsdellD., DouketisJ.D., Skrobik Y., Qushmaq I., Meade M., Guyatt G., Geerts W., Walsh M.W., Crowther M.A., Friedrich J.O., Burry L., Bellomo R., Brandao da Silva N., Costa Filho R., Cox M.J., Alves Silva S., Cook D.J.; PROTECT (Prophylaxis for Thromboembolism in Critical Care Trial)Investigators. Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: a subgroup analysis of the PROTECT trial. PLoS ONE. 2018; 13 (6): 0198285. DOI: 10.1371/jo-urnal.pone.0198285. PMID: 29856817

77. Moroz E. V, KarateevA.E., Kryukov E. V, Chernetsov VA. Gastrointestinal bleeding with the use of new oral anticoagulants: epidemiology, risk factors, treatment and prevention. Nauchno-prakticheskaya rev-matologiya. 2017; 55 (6): 675-684 [In Russ.]. dOi: 10.14412/1995-4484-2017-675-684.

78. Chi G., Gibson C., Kalayci A., Cohen A.T., Hernandez A.F., Hull R.D., Kahe F, Jafarizade M., Sharfaei S., Liu Y., Harrington R.A., Goldhaber S.Z. Extended-duration betrixaban versus shorter-duration enoxa-parin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. 2019; 45 (4) : 477-487. DOI: 10.1007/s00134-019-05565-6. PMID: 30778649

79. Rali P, Gangemi A., Moores A., Mohrien K., Moores L. Direct-Acting Oral Anticoagulants in Critically Ill Patients. Chest. 2019; 156 (3): 604-618. DOI: 10.1016/j.chest.2019.05.025. PMID: 31251908

80. Bertoletti L., Murgier M., Stelfox HT. Direct oral anticoagulants for venous thromboembolism prophylaxis in critically ill patients: where do we go from here? Intensive Care Med. 2019; 45 (4): 549-551. DOI: 10.1007/s00134-019-05605-1. PMID: 30911805

81. Hobson D.B., Chang T.Y., Aboagye J.K., Lau B.D., Shihab H.M., Fisher B., Young S., Sujeta N., Shaffer D.L., Popoola V.O., Kraus PS., Knorr G., Farrow N.E., StreiffM.B., Haut E.R. Prevalence of graduated compression stocking-associated pressure injuries in surgical intensive care units. J Crit Care. 2017; 40: 1-6. DOI: 10.1016/j.jcrc.2017.02.016. PMID: 28284096

82. Gibson C.D., Colvin M.O., Park M.J., Lai Q., Lin J., Negassa A., Shah C.D., Langston M.D. Prevalence and Predictors of Deep Vein Thrombosis in Critically Ill Medical Patients Who Underwent Diagnostic Duplex Ultrasonography. J Intensive Care Med. 2018; 885066618813300. DOI: 10.1177/0885066618813300. PMID: 30453801

83. Liew N.C., Chang Y.H., Choi G., Chu PH., Gao X., Gibbs H., Ho C.O., Ibrahim H., Kim T.K., KritprachaB., LeeL.H., LeeL., Lee W.Y., Li Y.J., Ni-colaides A.N., Oh D., Pratama D., Ramakrishnan N., Robless PA., Vil-larama-Alemany G., WongR.; Asian Venous Thrombosis Forum. Asian venous thromboembolism guidelines: prevention of venous thromboembolism. Int Angiol. 2012; 31 (6): 501-516. PMID: 23222928

84. BokarevI.N., PopovaL.V. Primary prevention of venous thromboembolism. In the book: Bokarev I.N., Popova L.V Venous thromboembolism and pulmonary thromboembolism. M.: Medical news agency; 2013: 281-293 [In Russ.].

85. Akchurin R. S., Arshinov A.V., Bokarev M. I., Borovkov N. N., Deryabin R. A., Kondratieva T. B., Kostin A. A., Kuznetsov M. R., Melnikov A. P, Nemirova S. V., Parfenov V. A., Petrukhin V. A., Pichugin V. V., Popova L. V., Sergeev S. V., Simonenko V B., Yakhno N. N., Bokarev I. N. (ed.), Medvedev A. P. (ed.). All - Russian Association for the Study of thrombosis, Hemorrhages and vascular Pathology named after A. A. Schmidt-B. A. Kudryashov. Diagnosis, treatment and prevention of venous thrombosis and pulmonary embolism. Guidelines. Moscow: P-Center; 2016: 84 [In Russ.].

86. Tamanna R. Venous Thromboembolism in Intensive Care Unit. University Heart Journal. 2009; 5 (2): 84-88. DOI: 10.3329/uhj.v5i2.4562.

87. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996; 26 (Suppl 2): 24-38. DOI: 10.1159/000217270. PMID: 8707165

88. Lim W., DentaliF, EikelboomJ.W., CrowtherM.A. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006; 144 (9): 673-684. DOI: 10.7326/0003-4819-144-9-200605020-00011. PMID: 16670137

89. Moiseev V S., Mukhin N. A., Smirnov A.V., Kobalava Zh. D., Bobkova I. N., Villevalde S. V., Efremovtseva M. A., Kozlovskaya L. V., Shvetsov M. Yu., Shestakova M. V. Cardiovascular Risk and Chronic Kidney Disease: Cardio-Nephroprotection Strategies. Eurasian Journal of InternalMedicine. 2014; 1 (4): 232-257 [In Russ.].

90. Al-Dorzi H.M., Tamim H.M., Aldawood AS., Arabi Y.M. Venous thromboembolism in critically ill cirrhotic patients: practices of prophylaxis and incidence. Thrombosis. 2013; 2013: 1-7. DOI: 10.1155/2013/807526. PMID: 24386564

91. Vignon P, Dequin P.F., Renault A., Mathonnet A., Paleiron N., Imbert A., Chatellier D., Gissot V, Lheritier G., Aboyans V, Prat G., Garot D., Boulain T., Diehl J.L., Bressollette L., Delluc A., Lacut K.; Clinical Research in Intensive Care and Sepsis Group (CRICS Group). Intermittent pneumatic compression to prevent venous thromboembolism in patients with high risk of bleeding hospitalized in intensive care units: the CIREA1 randomized trial. Intensive Care Med. 2013; 39 (5): 872-880. DOI: 10.1007/s00134-013-2814-2. PMID: 23370827

92. Warkentin T.E. Heparin-induced thrombocytopenia. Curr Opin Crit Care. 2015; 21 (6): 576-585. DOI: 10.1097/MCC.0000000000000259. PMID: 26539932

93. Dudarenko S.V, Ezhova O.A. Heparin-induced thrombocytopenia. Neotlozhnaya kardiologiya i kardiovaskulyarnye riski. 2018; 2 (1): 252-257 [In Russ.].

94. Kim S.C., TranN., ScheweJ.C., Boehm O., WittmannM., Graeff I., Hoeft A., Baumgarten G. Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis. J Cardiothorac Surg. 2015; 10: 19. DOI: 10.1186/s13019-015-0214-0. PMID: 25879883

95. Kang M., Alahmadi M., Sawh S., Ko vacs M.J., Lazo-Langner A. Fonda-parinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity scorematched study. Blood 2015; 125 (6): 924-929. DOI: 10.1182/blood-2014-09-599498. PMID: 25515959

96. Pappalardo F, Covello R.D., Pieri M., Agracheva N., De Bonis M., Calabrd M.G., Koster A., Zangrillo A. Anticoagulation for critically ill cardiac surgery patients: is primary bivalirudin the next step? J Cardiot-horac Vasc Anesth. 2014; 28 (4): 1013-1017. DOI: 10.1053/j.jvca.2013.10.004. PMID: 24447496

97. Tardy-Poncet B., Wolf M., Lasne D., Bauters A., Ffrench P, Elalamy I., Tardy B. Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases. Intensive Care Med. 2009; 35 (8): 1449-1453. DOI: 10.1007/s00134-009-1464-x. PMID: 19350215

98. Srinivasan A.F., Rice L., Bartholomew J.R., Rangaswamy C., La Perna L., Thompson J.E., Murphy S., Baker K.R. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med. 2004; 164 (1): 66-70. DOI: 10.1001/archinte.164.1.66. PMID: 14718324

99. Tardy-Poncet B., Nguyen P, Thiranos J.C., Morange PE., Biron-An-dreani C., Gruel Y., Morel J., Wynckel A., Grunebaum L., Villacorta-Torres J., Grosjean S., de Maistre E. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. Crit Care 2015; 19: 396. DOI: 10.1186/s13054-015-1109-0. PMID: 26556106